Women in Lithuania battling breast cancer have faced shortages of the essential drug Tamoxifen for four consecutive months, prompting some to seek treatment in neighboring Latvia and Poland.
Supply Disruptions and Patient Impact
Ineta Jokubauskienė, a resident of Šiauliai who has been fighting breast cancer for two years, relies on daily doses of Tamoxifen to ensure successful treatment and prevent recurrence. However, she and other patients have struggled to find the medication within Lithuania. Jokubauskienė reported searching pharmacies throughout the country, and while she eventually secured a supply, others have been forced to travel to Latvia or Poland, where Tamoxifen is available with a paper prescription.
The Oncology Patients’ Support Association has received complaints about the shortages, calling the situation “unprecedented.” Neringa Čakienė, the association’s director, noted that some patients have been without the medication since November. The limited availability has also led to increased costs, with some patients paying more for the drug when they can find it.
Conflicting Reports and Proposed Solutions
The Lithuanian State Medicines Agency acknowledges past supply problems in November but asserts that the drug is now available in sufficient quantities. Dovilė Marcinkė, the agency’s head, suggested that pharmacies may not be ordering enough of the medication or that patients are requesting excessively large, six-month supplies. Pharmacies, however, dispute these claims, stating that difficulties arise when they are unable to secure the medication from suppliers, even when orders are placed.
In response to the ongoing disruptions, the Lithuanian Ministry of Health has recommended that pharmacies limit sales to a one-month supply per patient. However, patient rights groups maintain that women should be able to purchase the amount prescribed by their doctors, particularly those living in remote areas.
Looking Ahead
The Lithuanian government plans to amend the Pharmaceutical Law this fall, aiming to streamline procedures and address accessibility issues. It remains to be seen whether these changes will resolve the current Tamoxifen shortage and prevent future disruptions. If the supply chain issues persist, patients may continue to face challenges accessing this vital medication, potentially impacting their treatment outcomes. Further disruptions to medication availability could also fuel public distrust in the healthcare system.
Frequently Asked Questions
What is Tamoxifen used for?
Tamoxifen is used primarily in the prevention and treatment of breast cancer, inhibiting the growth-promoting actions of estrogen in breast cancer cells.
Where are patients seeking Tamoxifen when it is unavailable in Lithuania?
Some patients are traveling to Latvia or Poland to purchase Tamoxifen, where it can be obtained with a paper prescription.
What is the Lithuanian State Medicines Agency’s response to the shortages?
The agency insists that there were supply problems in November, but that the drug is now available in sufficient quantities in the country and that alternatives with the same active ingredient are available.
How might ongoing medication shortages affect patients beyond the immediate health concerns?
